Bull&Bear | MicroAlgo Leads Stock Surge with 455% Rise Amid Convertible Bond News

In the world of booming stocks:

MicroAlgo (MLGO) surged by 455.16%. The company recently announced that it is adhering to the terms of the convertible bond purchase agreement signed on October 7, 2024. This move is expected to boost investor confidence and drive the stock price higher.

Lexeo Therapeutics (LXEO) saw a rise of 50.92%, marking two consecutive days of gains with a cumulative increase of 52.04%. The upward momentum in Lexeo Therapeutics' stock stems from the company reporting year-over-year growth in earnings per share for the fourth quarter.

Lotus Technology (LOT) experienced a gain of 38.61%, extending its two-day rally to a total surge of 46.00%. The rise was fueled by Lotus Technology signing a strategic agreement with Cao Movilidad.

Tonix Pharmaceuticals (TNXP) increased by 32.48%, achieving a three-day climb of 85.25%. The pharmaceutical company's stock rose following the announcement that the FDA will not require an advisory committee review for Tnx-102 SI.

Intuitive Machines (LUNR) ascended by 30.04%. Roth MKM maintained a buy rating for Intuitive Machines and kept the target price at $12. This rating reflects positive sentiment from analysts regarding the company's future performance, potentially attracting more investor attention and investment.

In the realm of declining stocks:

Regen BioScience (RGC) fell by 30.07%. However, in pre-market trading, the biotechnology company saw an increase of over 22%, following a previous day's gain of more than 46%.

Luminar Technologies (LAZR) decreased by 23.23%. The company has outlined a "conservative" outlook for 2025, contributing to the decline in stock value.

Network Technology (NTCL) dropped by 22.97%. The overall market weakness, driven by concerns over U.S. consumer sentiment and economic conditions, is affecting the stocks of companies in the broad consumer sector.

Wellgistics (WGRX) tumbled by 20.36%. Wellgistics Health, Inc. announced changes in leadership, appointing Brian Norton as CEO, following Tim Kanning's resignation.

Parkho Biosciences (PHH) decreased by 19.73%. The biotech firm released a foreign issuer report (6-K) related to its performance, impacting stock price accordingly.